-

10:37:40 PM

SCPH Stock News

SCPH - scPharmaceuticals Inc

09/19/23 8:00 AM

Nasdaq : SCPH

low float

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients Agency confirms no additional clinical data required to pursue label expansion of FUROSCIX into chronic

RHEA-AI

neutral

09/05/23 8:00 AM

Nasdaq : SCPH

conferenceslow float

scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today

RHEA-AI

neutral

08/10/23 4:01 PM

Nasdaq : SCPH

earningslow float

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

RHEA-AI

neutral

08/03/23 8:00 AM

Nasdaq : SCPH

earningslow float

scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient

RHEA-AI

neutral

08/01/23 8:00 AM

Nasdaq : SCPH

low float

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the

RHEA-AI

neutral

07/19/23 8:00 AM

Nasdaq : SCPH

low float

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare

RHEA-AI

positive

06/23/23 8:00 AM

Nasdaq : SCPH

low float

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today

RHEA-AI

neutral

05/31/23 8:00 AM

Nasdaq : SCPH

conferenceslow float

scPharmaceuticals to Present at the Jefferies Healthcare Conference

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today

RHEA-AI

neutral

05/10/23 4:01 PM

Nasdaq : SCPH

earningslow float

scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Announced launch and commercial availability of FUROSCIX® on February 20 th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments o f $116.1 million Company to host investor conference call and webcast today, Wednesday, May 10, at 4:30pm

RHEA-AI

neutral

05/02/23 8:00 AM

Nasdaq : SCPH

earningslow float

scPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient

RHEA-AI

neutral

1 2 3 4 5 6 7 Next